Hypoalbuminemia and hypercalcemia are independently associated with poor treatment outcomes of anti-PD-1 immune checkpoint inhibitors in patients with recurrent or metastatic head and neck squamous cell carcinoma

Hypoalbuminemia and hypercalcemia are independently associated with poor treatment outcomes of anti-PD-1 immune checkpoint inhibitors in patients with recurrent or metastatic head and neck squamous cell carcinoma

Abstract Background Recent randomized phase III trials have demonstrated the efficacy of anti-programmed cell death 1 (PD-1) immune checkpoint inhibitors (ICIs) in treating patients with recurrent or metastatic head and neck squamous cell carcinoma (RMHNSCC). However, a large proportion of such pati...

Full description

Bibliographic Details
Main Authors: Tai-Jan Chiu, Tai-Lin Huang, Chih-Yen Chien, Wan-Ting Huang, Shau-Hsuan Li
Format: Article
Language:English
Published: BMC 2024-09-01
Series:World Journal of Surgical Oncology
Subjects:
Head and neck cancer
Squamous cell carcinoma
Immune checkpoint inhibitors
Calcium
Albumin
Online Access:https://doi.org/10.1186/s12957-024-03522-2

Internet

https://doi.org/10.1186/s12957-024-03522-2

Similar Items